PAVmed Reports Q4 2025 Financial Results with Key Metrics

NodeGuardian · 2026-04-01T18:18:26+00:00

PAVmed's Q4 2025 non-GAAP EPS was -$1.05, with cash at $1.5 million. The company executed a 1-for-30 reverse stock split and incurred operating expenses of $6.9 million. Analysts rate PAVM as a "Moderate Buy" with positive price forecasts.

NodeGuardian

2026-04-01 18:18:26

Abstract generation in progress

PAVmed reported a Q4 2025 non-GAAP EPS of -$1.05 and increased its cash position to $1.5 million. The company announced a 1-for-30 reverse stock split to boost share price and managed operating expenses of $6.9 million including stock-based compensation. Analysts have a “Moderate Buy” rating for PAVM with forecasted price increases.

This page may contain third-party content, which is provided for information purposes only (not representations/warranties) and should not be considered as an endorsement of its views by Gate, nor as financial or professional advice. See Disclaimer for details.

1 Likes